Get access

Propranolol for airway hemangiomas: Case report of novel treatment

Authors

  • Lisa Buckmiller MD,

    Corresponding author
    1. Department of Otolaryngology, Division of Pediatric Otolaryngology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, U.S.A
    • Arkansas Children's Hospital, 1 Children's Way Slot 668, Little Rock, AR 72202
    Search for more papers by this author
  • Umesh Dyamenahalli MD,

    1. Department of Otolaryngology, Division of Pediatric Otolaryngology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, U.S.A
    Search for more papers by this author
  • Gresham T. Richter MD

    1. Department of Otolaryngology, Division of Pediatric Otolaryngology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, U.S.A
    Search for more papers by this author

Abstract

Infantile hemangiomas arising in the trachea are rare. These lesions pose a management dilemma as several treatment options can provide safe management. Propranolol, a nonselective beta-blocker, has recently been introduced as a novel modality for the treatment of proliferating hemangiomas. This report illustrates the successful management of tracheal hemangiomas using oral propranolol in a young patient with otherwise treatment-resistant airway lesions. Despite various endoscopic therapeutic attempts, the patient remained stridulous with airway disease that persisted into the involution phase of the average hemangioma cycle. Within 6 weeks of beginning oral propranolol (2 mg/kg/day), her airway compromise was eliminated and she had complete resolution of endoscopically visible disease. No side effects from propranolol occurred. We propose that oral propranolol should be considered for use in airway hemangiomas. Laryngoscope, 2009

Get access to the full text of this article

Ancillary